Cited by

• At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.

  Ganzel C, Wang XV, Rowe JM, Richards SM, Buck G, Marks DI, Litzow MR, Paietta EM, Foroni L, Luger SM, Willman CL, Mullighan CG, Roberts KG, Wiernik PH, Douer D, Lazarus HM, Tallman MS, Goldstone AH. Ganzel C, et al. Br J Haematol. 2020 Oct;191(1):37-43. doi: 10.1111/bjh.16616. Epub 2020 Mar 27. Br J Haematol. 2020. PMID: 32220069 Free PMC article. Clinical Trial.
• MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).

  Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ. Sobulo OM, et al. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8732-7. doi: 10.1073/pnas.94.16.8732. Proc Natl Acad Sci U S A. 1997. PMID: 9238046 Free PMC article.
• [Secondary myelodysplastic syndrome in a patient with de novo t(8;21) acute myeloid leukemia: a case report and literatures review].

  Lin D, Zhang GJ, Mi YC, Wang JX. Lin D, et al. Zhonghua Xue Ye Xue Za Zhi. 2018 Jan 14;39(1):50-52. doi: 10.3760/cma.j.issn.0253-2727.2018.01.011. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29551034 Free PMC article. Chinese. No abstract available.
• Polymorphisms in the MLL breakpoint cluster region (BCR).

  Echlin-Bell DR, Smith LL, Li L, Strissel PL, Strick R, Gupta V, Banerjee J, Larson R, Relling MV, Raimondi SC, Hayashi Y, Taki T, Zeleznik-Le N, Rowley JD. Echlin-Bell DR, et al. Hum Genet. 2003 Jul;113(1):80-91. doi: 10.1007/s00439-003-0936-2. Epub 2003 Mar 29. Hum Genet. 2003. PMID: 12665971
• Cracking the cytotoxicity code: apoptotic induction of 10-acetylirciformonin B is mediated through ROS generation and mitochondrial dysfunction.

  Shih HC, El-Shazly M, Juan YS, Chang CY, Su JH, Chen YC, Shih SP, Chen HM, Wu YC, Lu MC. Shih HC, et al. Mar Drugs. 2014 May 22;12(5):3072-90. doi: 10.3390/md12053072. Mar Drugs. 2014. PMID: 24857964 Free PMC article.